Prostate Cancer (Adenocarcinoma)Phase 2NCT07907653
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
A Phase 2 study testing Deutenzalutamide, Docetaxel and ADT in people with Prostate Cancer (Adenocarcinoma), run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
Trial summary
This study will assess the effects and safety of deutenzalutamide combined with hormone therapy before and after prostate cancer surgery, with docetaxel chemotherapy added before surgery. Read more about this study
- Who is it for?
- Ages 18 to 80 years, men only
- Conditions the study is for
- Prostate Cancer (Adenocarcinoma)
- What is being tested?
- Deutenzalutamide, Docetaxel and ADT
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 37 participants
- Where
- 1 siteChina
- Study dates
- Nov 2026to Jan 2035
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men aged 18-80 years with histologically confirmed high-risk localized or locally advanced prostate adenocarcinoma.
- High-risk disease is defined by meeting either (1) or (2):
- NCCN high-risk criteria: at least one of the following:Gleason score >=8;Prostate-specific antigen (PSA) >=20 ng/mL;Clinical T stage >=T3.
- Study-specific biopsy criteria: overall Gleason score >=4+3 (International Society of Urological Pathology [ISUP] Grade Group [GG] 3-5), plus at least one of the following:(a) >=6 systematic biopsy cores showing Gleason 4+3 (GG3) or Gleason 8 (4+4 or 5+3), including at least one Gleason-8 core. Only systematic cores are counted; targeted cores are excluded from this count;(b) >=3 systematic biopsy cores showing Gleason 4+3 (GG3) or Gleason 8 (4+4 or 5+3), PSA >=20 ng/mL, and at least one Gleason-8 core. Only systematic cores are counted; targeted cores are excluded from this count;(c) >=1 systematic or targeted biopsy core with Gleason score >=9 (GG5). Both systematic and targeted cores may be counted, without counting the same core more than once;(d) >=2 distinct, evaluable systematic or targeted biopsy cores, each with Gleason score >=8 (GG4-5) and tumor involvement >=80%. Core counting and tumor involvement are determined according to the protocol's standardized rules.
- No distant metastases (cM0) on baseline imaging; cN0 or pelvic cN1 below the common iliac artery bifurcation is permitted. Suitable for radical prostatectomy and pelvic lymph node dissection.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1; life expectancy >=10 years; able to receive androgen-deprivation therapy for >=13 months.
Show all 9Show fewer
- Adequate organ function, assessed after >=14 days without blood-component transfusion or hematopoietic support: neutrophils >=1.5 x 10^9/L; platelets >=100 x 10^9/L; hemoglobin >=9 g/dL; potassium >=3.5 mmol/L; ALT and AST <=2.5 times the upper limit of normal (ULN); total bilirubin <=1.5 x ULN; creatinine <1.5 x ULN; albumin >=3.0 g/dL; international normalized ratio (INR) <1.5. Eligibility during therapeutic anticoagulation requires investigator assessment.
- Able to swallow capsules, without significant swallowing difficulty or a history of severe gastrointestinal malabsorption.
- Written informed consent and willingness to comply with study procedures and applicable contraception requirements.
Who cannot join
- Neuroendocrine/small-cell prostate carcinoma, distant metastases, or previous local or systemic treatment for prostate cancer.
- Allergy to study drugs, excipients or drugs of the same class; contraindications to docetaxel or prednisone acetate, including active infection.
- Need for chronic systemic glucocorticoids exceeding a total prednisone-equivalent dose of 10 mg/day during study treatment.
- Poorly controlled hypertension despite treatment: systolic >=160 mmHg or diastolic >=95 mmHg.
- Active or symptomatic viral hepatitis or other chronic liver disease; known HIV infection.
- History of pituitary or adrenal dysfunction; active autoimmune disease requiring corticosteroids.
Show all 16Show fewer
- Serious cardiovascular/cerebrovascular disease within 6 months before study treatment, including severe/unstable angina, myocardial infarction, New York Heart Association class III-IV heart failure, stroke, or arrhythmia requiring medication.
- Previous allogeneic organ or hematopoietic stem-cell transplantation.
- Grade >=2 peripheral sensory or motor neuropathy.
- Another malignancy currently or within the previous 2 years.
- Major surgery requiring general anesthesia within 28 days before the first dose.
- Use of prohibited urinary-symptom or PSA-altering medications during deutenzalutamide treatment, including finasteride, dutasteride or phytoestrogens.
- Seizure history or conditions increasing seizure risk, including stroke within 1 year before the first study anticancer dose or cerebral arteriovenous malformation; benign central nervous system/meningeal disease expected to require surgery or radiotherapy during study treatment.
- Alcohol or drug abuse/dependence.
- Participation in another therapeutic clinical trial within 1 month before study treatment.
- Any other condition considered unsuitable by the investigator.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, 510120
About this study
Official title: POST-PC-01: A Prospective, Multicenter, Single-Arm, Open-Label, Exploratory Study of Perioperative Deutenzalutamide Plus Androgen-Deprivation Therapy With the Addition of Docetaxel in the Neoadjuvant Phase in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
This study will assess the effects and safety of deutenzalutamide combined with hormone therapy before and after prostate cancer surgery, with docetaxel chemotherapy added before surgery. It is intended for men with high-risk localized or locally advanced prostate cancer who have no distant spread on imaging and are suitable for surgery.
The researchers will measure how often treatment leaves no cancer or only a very small amount of cancer in the prostate, with no cancer in the pelvic lymph nodes removed during surgery. They will also assess whether participants can undergo the planned surgery, what side effects occur, and whether the cancer returns or spreads during follow-up.
Read more
Up to 37 participants will be enrolled at several hospitals. All participants will be assigned to the same treatment plan; there is no comparison group.
The planned treatment includes:
- Deutenzalutamide taken by mouth each day, together with hormone therapy to lower testosterone levels, for 24 weeks before surgery.
- Docetaxel given through a vein once every 3 weeks for six cycles during the treatment period before surgery.
- Surgery to remove the prostate and pelvic lymph nodes, when medically appropriate.
- A further 24 weeks of deutenzalutamide and hormone therapy after recovery from surgery, without further docetaxel.
Hormone therapy will continue across the treatment periods for a total of at least 13 months. Treatment may be adjusted or stopped according to side effects and the participant's condition. Follow-up is planned for up to 5 years after all study treatment has ended.
Participants may also choose to join an optional study using a single blood sample collected before treatment and leftover tissue from their diagnostic prostate biopsy. These samples will be used to explore features that may be associated with treatment response and later outcomes. Participation in this optional component is not required to receive the study treatment.
Read the detailed description
POST-PC-01 is an investigator-initiated, prospective, multicenter, single-arm, open-label exploratory study. The rationale is to combine androgen receptor pathway inhibition and androgen deprivation with chemotherapy before definitive surgery, while limiting docetaxel exposure to the preoperative period. The study will generate preliminary evidence on antitumor activity, safety, and clinical feasibility; it is not designed to establish superiority over another treatment.
The study uses a Simon minimax two-stage design. The first stage includes 16 participants in the prespecified primary efficacy decision analysis set. Enrollment will proceed to the second stage only if the first-stage results meet the predefined continuation criterion. The second stage adds 15 participants, for a total of 31 participants in the decision analysis set. The maximum enrollment of 37 allows limited replacement under protocol-defined circumstances unrelated to treatment efficacy or tolerability. Participants unable to undergo surgery because of disease progression or treatment toxicity are counted as nonresponders rather than replaced.
The optional exploratory component is limited to pretreatment samples. It includes one peripheral blood collection of 20 mL for genetic analysis and the use of residual tissue from the diagnostic prostate biopsy. Tissue assessments include intraductal carcinoma of the prostate, BRCA1 and BRCA2 and other DNA repair-related gene alterations, and PTEN deletion or related abnormalities. No additional biopsy is performed for this component.
Where samples and outcome data are available, associations between baseline pathological or genetic features and pathological response, recurrence, or progression will be explored descriptively. Participation requires an affirmative choice within the study informed consent form. Declining or withdrawing from this optional component does not affect participation in the study treatment and follow-up.
- Conditions
- Prostate Cancer (Adenocarcinoma)
- Being tested
- Deutenzalutamide, Docetaxel, ADT
- Medical subject headings
- Prostatic Neoplasms, Adenocarcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DeutenzalutamideDrug
Deutenzalutamide 80 mg is administered orally once daily with androgen deprivation therapy (ADT) for 24 weeks before radical prostatectomy. After adequate postoperative recovery, deutenzalutamide is planned to resume approximately 4 weeks after surgery at the last tolerated dose, with ADT, for an additional 24 weeks. Dose modifications and treatment interruptions are managed according to the protocol.
DocetaxelDrug
Docetaxel 60 mg/m² is administered by intravenous infusion every 3 weeks for 6 cycles (planned at Weeks 0, 3, 6, 9, 12, and 15) during neoadjuvant treatment, in combination with deutenzalutamide and androgen deprivation therapy (ADT). Treatment interruptions and discontinuation follow protocol-defined criteria; docetaxel is not administered during postoperative adjuvant treatment.
ADTDrug
Androgen deprivation therapy (ADT) is administered according to the prescribing information for the selected agent. Treatment begins in the neoadjuvant phase and continues through the perioperative and postoperative adjuvant phases for a total duration of at least 13 months.
| Study group | Role | What they receive |
|---|---|---|
| Perioperative Deutenzalutamide Plus Androgen Deprivation Therapy With Neoadjuvant Docetaxel | Experimental | Neoadjuvant treatment: deutenzalutamide 80 mg orally once daily plus androgen deprivation therapy (ADT) for 24 weeks, with docetaxel 60 mg/m2 intravenously every 3 weeks for 6 cycles. Prednisone acetate 5 mg orally twice daily is given during docetaxel treatment, with subsequent tapering/discontinuation according to the protocol. When medically appropriate, participants undergo radical prostatectomy with pelvic lymph node dissection approximately 2 weeks after neoadjuvant treatment. After adequate postoperative recovery, deutenzalutamide is resumed at the last tolerated dose with ADT for 24 weeks, starting approximately 4 weeks after surgery. No postoperative docetaxel is given. ADT continues throughout for a total of at least 13 months. Dose modifications and treatment interruptions follow the protocol. Receives: Drug: Deutenzalutamide; Drug: Docetaxel; Drug: ADT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pathological Complete Response or Minimal Residual Disease (pCR/MRD) Rate
Percentage of participants in the prespecified primary efficacy decision analysis set who achieve pCR or MRD on pathological examination of radical prostatectomy and pelvic lymph node dissection specimens after neoadjuvant treatment. pCR is defined as no identifiable residual cancer in the prostate (ypT0) and no regional lymph node metastasis (ypN0). MRD is defined as residual cancer confined to the prostate (ypT2 or lower), with the largest residual tumor focus measuring no more than 5 mm in greatest dimension, and ypN0. Both require no confirmed distant metastasis at assessment. Each participant is counted once. Participants unable to undergo surgery within 56 days after the actual end of neoadjuvant treatment because of disease progression, treatment toxicity or intolerance are counted as nonresponders. Other unassessable cases are handled according to the prespecified protocol rules.
Measured: At postoperative pathological assessment (surgery planned approximately 26 weeks after treatment initiation; qualifying surgery within 56 days after the actual end of neoadjuvant treatment).
Secondary outcomes (20)
Metastasis-Free Survival (MFS)
Time from the first administration of study anticancer treatment to the first occurrence of distant metastasis confirmed by imaging (PSMA-PET/CT or conventional imaging) or pathology, or death from any cause, whichever occurs first. Distant metastasis includes nonregional lymph node, bone, or visceral metastasis. Regional pelvic lymph node involvement alone is not considered distant metastasis.
Measured: From the first dose of study anticancer treatment to distant metastasis or death, whichever occurs first, with follow-up through 60 months after the end of all study treatment.
Event-Free Survival (EFS)
Time from the first dose of study anticancer treatment to the earliest of: (1) biochemical failure after radical prostatectomy (RP), defined as serum prostate-specific antigen (PSA) >=0.2 ng/mL confirmed by another value >=0.2 ng/mL at least 1 week later; (2) imaging- or pathology-confirmed local or regional recurrence; (3) imaging- or pathology-confirmed distant metastasis; or (4) death from any cause. The event date for biochemical failure is the date of the first qualifying PSA sample, including for confirmed persistent postoperative PSA. Biochemical failure does not require imaging-confirmed recurrence. Preoperative local or regional progression, including progression preventing RP, is not an EFS event; preoperative distant metastasis or death is an event. Positive surgical margins, positive pathological lymph nodes, or failure to achieve pCR/MRD do not automatically constitute EFS events.
Measured: From the first dose of study anticancer treatment to the first qualifying EFS event, with follow-up through 60 months after the end of all study treatment.
Time to Distant Metastasis
Time from the first dose of study anticancer treatment to the first distant metastasis confirmed by imaging (PSMA-PET/CT or conventional imaging) or pathology. Distant metastasis includes nonregional lymph node, bone, or visceral metastasis. Regional pelvic lymph node involvement alone is not considered distant metastasis. Death without prior distant metastasis is not counted as a distant metastasis event. Competing risks are addressed as prespecified in the statistical analysis plan.
Measured: From the first dose of study anticancer treatment to the first confirmed distant metastasis, with follow-up through 60 months after the end of all study treatment.
Time to First Subsequent Anticancer Therapy
Time from the first dose of study anticancer treatment to the initiation of the first subsequent anticancer therapy outside the protocol-defined treatment regimen for prostate cancer recurrence, progression, or other disease-related reasons. Subsequent therapy may include radiotherapy, endocrine therapy, androgen receptor pathway inhibitors, chemotherapy, radionuclide therapy, or other systemic anticancer treatments. Protocol-specified neoadjuvant and adjuvant treatments are not counted as subsequent therapy. Competing risks are addressed as prespecified in the statistical analysis plan.
Measured: From the first dose of study anticancer treatment to initiation of the first subsequent anticancer therapy, with follow-up through 60 months after the end of all study treatment.
Biochemical Recurrence-Free Survival (bRFS)
Time from radical prostatectomy (RP) to the first occurrence of biochemical recurrence (BCR) or death from any cause, whichever occurs first. BCR is defined as postoperative serum prostate-specific antigen (PSA) >=0.2 ng/mL, confirmed by a subsequent PSA measurement >=0.2 ng/mL at least 1 week later. The BCR event date is the date of the first qualifying PSA sample. Participants with persistent postoperative PSA >=0.2 ng/mL also require subsequent confirmation; the event date is the date of the first postoperative sample meeting this threshold, and PSA persistence is recorded separately. Imaging-confirmed recurrence is not required.
Measured: From radical prostatectomy to biochemical recurrence or death, whichever occurs first, with follow-up through 60 months after the end of all study treatment.
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Percentage of participants in the safety analysis set who experience at least one treatment-emergent adverse event (TEAE). A TEAE is an adverse event that first occurs or worsens after the first dose of protocol-specified study treatment during the safety observation period, regardless of its relationship to treatment. Events are coded using MedDRA and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 6.0. Severity and relationship to study treatment are summarized. Safety is assessed across the neoadjuvant, surgical, and adjuvant treatment phases.
Measured: From the first dose of protocol-specified anticancer treatment through 30 days after the end of all study treatment.
Percentage of Participants With Grade 3 or Higher Adverse Events
Percentage of participants in the safety analysis set who experience at least one Grade 3 or higher adverse event during the safety observation period, regardless of its relationship to study treatment. Severity is graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 6.0. Grade 3 indicates severe events, Grade 4 indicates life-threatening events, and Grade 5 indicates death related to an adverse event. Assessment covers the neoadjuvant, surgical, and adjuvant treatment phases.
Measured: From the first dose of protocol-specified anticancer treatment through 30 days after the end of all study treatment.
Percentage of Participants With Serious Adverse Events (SAEs)
Percentage of participants in the safety analysis set who experience at least one serious adverse event (SAE) during the safety observation period, regardless of its relationship to study treatment. An SAE is an event that results in death, is life-threatening, requires unplanned hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, causes a congenital anomaly or birth defect, or is another important medical event that may jeopardize the participant or require medical or surgical intervention to prevent such outcomes. Planned hospitalization for radical prostatectomy alone is not considered an SAE; complications requiring unplanned admission, readmission, or prolonged hospitalization are assessed against the SAE criteria. Seriousness is assessed separately from NCI-CTCAE severity grading.
Measured: From the first dose of protocol-specified anticancer treatment through 30 days after the end of all study treatment.
Percentage of Participants With Adverse Events Leading to Study Drug Interruption, Dose Modification, or Permanent Discontinuation
Percentage of participants in the safety analysis set who experience at least one adverse event leading to temporary interruption, dose modification, or permanent discontinuation of a study drug. For each event, the affected drug, action taken, severity, relationship to treatment, and outcome are recorded. Severity is graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 6.0. Assessment covers the neoadjuvant, surgical, and adjuvant treatment phases. Planned treatment completion or protocol-specified interruptions not caused by an adverse event are not counted.
Measured: From the first dose of protocol-specified anticancer treatment through 30 days after the end of all study treatment.
Percentage of Participants With Treatment-Related Deaths
Percentage of participants in the safety analysis set who die from an adverse event assessed by the investigator as related to study treatment. Related events include those judged definitely, probably, or possibly related to a protocol-specified study intervention; deaths assessed as unlikely related or unrelated are excluded from this endpoint.
Measured: From the first dose of protocol-specified anticancer treatment through 30 days after the end of all study treatment.
Serum Prostate-Specific Antigen (PSA) Level at the End of Neoadjuvant Treatment
Serum prostate-specific antigen (PSA) concentration is measured in ng/mL at the end of neoadjuvant treatment, before radical prostatectomy. The absolute PSA value at this assessment is summarized using descriptive statistics.
Measured: At the end of neoadjuvant treatment (planned at Week 24), before radical prostatectomy.
Serum Prostate-Specific Antigen (PSA) Levels After Radical Prostatectomy and During Adjuvant Treatment
Serum prostate-specific antigen (PSA) concentration, expressed in ng/mL, is measured after radical prostatectomy at the adjuvant treatment baseline and at scheduled visits during adjuvant treatment. PSA values are summarized descriptively at each assessment to characterize postoperative PSA dynamics.
Measured: At adjuvant treatment baseline (approximately 4 weeks after radical prostatectomy) and at adjuvant Weeks 4, 8, 12, 16, 20, and 24/end of treatment.
Pathological Primary Tumor Stage (ypT) After Neoadjuvant Treatment
Pathological primary tumor stage (ypT) is determined by histopathological examination of radical prostatectomy specimens obtained after neoadjuvant treatment. The number and percentage of participants in each ypT category are summarized.
Measured: At final postoperative pathological assessment following radical prostatectomy (surgery planned approximately 26 weeks after treatment initiation).
Pathological Regional Lymph Node Stage (ypN) After Neoadjuvant Treatment
Pathological regional lymph node stage (ypN) is determined by histopathological examination of pelvic lymph node dissection specimens obtained at radical prostatectomy. The number and percentage of participants in each ypN category are summarized, with unknown or unevaluable nodal status reported separately.
Measured: At final postoperative pathological assessment following radical prostatectomy (surgery planned approximately 26 weeks after treatment initiation).
Composite Pathological Downstaging Rate (T and/or N)
Percentage of participants with pathological downstaging, assessed by comparing postoperative pathological T and N categories (ypT and ypN) with pretreatment clinical categories (cT and cN). Downstaging requires a lower T category and/or conversion from cN1 to ypN0, with no worsening of either category. Each participant meeting this composite definition is counted once.
Measured: From pretreatment baseline to final postoperative pathological assessment (surgery planned approximately 26 weeks after treatment initiation).
Positive Surgical Margin Rate
Percentage of participants with a positive surgical margin on final histopathological examination of the radical prostatectomy specimen after neoadjuvant treatment. A positive margin is defined as tumor cells touching the inked resection surface.
Measured: At final postoperative pathological assessment following radical prostatectomy (surgery planned approximately 26 weeks after treatment initiation).
Objective Response Rate (ORR) at the End of Neoadjuvant Treatment
Objective response rate is the percentage of participants in the full analysis set with measurable disease at baseline who achieve an overall complete or partial response. Response is assessed by imaging according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at the end of neoadjuvant treatment, before radical prostatectomy.
Measured: At the end of neoadjuvant treatment (planned at Week 24), before radical prostatectomy.
Radical Prostatectomy Rate
Percentage of participants in the full analysis set who undergo radical prostatectomy following neoadjuvant study treatment. Surgical status is determined from operative records, and reasons for not undergoing surgery are documented.
Measured: During the surgical phase following neoadjuvant treatment (radical prostatectomy planned approximately 26 weeks after treatment initiation).
Rate of Radical Prostatectomy Delay Due to Treatment-Related Adverse Events
Percentage of participants whose planned radical prostatectomy is delayed because of an adverse event assessed by the investigator as related to study treatment. Related events include those considered definitely, probably, or possibly related; delays solely due to reasons unrelated to study treatment are excluded.
Measured: From initiation of neoadjuvant treatment through the surgical phase (radical prostatectomy planned approximately 26 weeks after treatment initiation).
Incidence and Severity of Postoperative Complications
Percentage of participants undergoing radical prostatectomy who experience at least one postoperative complication. Complications are summarized by type and severity using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0, with investigator clinical judgment for events not specifically covered by CTCAE.
Measured: From radical prostatectomy through the adjuvant baseline visit (approximately 4 weeks postoperatively), with additional assessment at adjuvant Week 4 (approximately 8 weeks postoperatively) as clinically indicated.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2026
- Study startNov 2026 (estimated)
- Primary completionJul 2029 (estimated)
- Study completionJan 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate Cancer (Adenocarcinoma)Studies of the same condition, open and under way.
- More trials run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 37 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Hinova Pharmaceuticals Inc.
- Responsible party
- Principal investigator, Dong Wen, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07907653
- Sponsor's protocol ID
- POST-PC-01
- Status last verified
- Oct 2026
- First submitted
- 25 Oct 2026
- Last updated
- 30 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- POST-PC-01: A Prospective, Multicenter, Single-Arm, Open-Label, Exploratory Study of Perioperative Deutenzalutamide Plus Androgen-Deprivation Therapy With the Addition of Docetaxel in the Neoadjuvant Phase in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
- ClinicalTrials.gov ID
- NCT07907653
- Acronym / sponsor ID
- POST-PC-01
- Conditions
- Prostate Cancer (Adenocarcinoma)
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 37 participants (estimated)
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUniversity, hospital or other
- Collaborators
- Hinova Pharmaceuticals Inc.
- Study start
- Nov 2026 (estimated)
- Primary completion
- Jul 2029 (estimated)
- Study completion
- Jan 2035 (estimated)
- First posted
- 30 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will assess the effects and safety of deutenzalutamide combined with hormone therapy before and after prostate cancer surgery, with docetaxel chemotherapy added before surgery. It is intended for men with high-risk localized or locally advanced prostate cancer who have no distant spread on imaging and are suitable for surgery.
The researchers will measure how often treatment leaves no cancer or only a very small amount of cancer in the prostate, with no cancer in the pelvic lymph nodes removed during surgery. They will also assess whether participants can undergo the planned surgery, what side effects occur, and whether the cancer returns or spreads during follow-up.
Up to 37 participants will be enrolled at several hospitals. All participants will be assigned to the same treatment plan; there is no comparison group.
The planned treatment includes:
- Deutenzalutamide taken by mouth each day, together with hormone therapy to lower testosterone levels, for 24 weeks before surgery.
- Docetaxel given through a vein once every 3 weeks for six cycles during the treatment period before surgery.
- Surgery to remove the prostate and pelvic lymph nodes, when medically appropriate.
- A further 24 weeks of deutenzalutamide and hormone therapy after recovery from surgery, without further docetaxel.
Hormone therapy will continue across the treatment periods for a total of at least 13 months. Treatment may be adjusted or stopped according to side effects and the participant's condition. Follow-up is planned for up to 5 years after all study treatment has ended.
Participants may also choose to join an optional study using a single blood sample collected before treatment and leftover tissue from their diagnostic prostate biopsy. These samples will be used to explore features that may be associated with treatment response and later outcomes. Participation in this optional component is not required to receive the study treatment.
Detailed description
POST-PC-01 is an investigator-initiated, prospective, multicenter, single-arm, open-label exploratory study. The rationale is to combine androgen receptor pathway inhibition and androgen deprivation with chemotherapy before definitive surgery, while limiting docetaxel exposure to the preoperative period. The study will generate preliminary evidence on antitumor activity, safety, and clinical feasibility; it is not designed to establish superiority over another treatment.
The study uses a Simon minimax two-stage design. The first stage includes 16 participants in the prespecified primary efficacy decision analysis set. Enrollment will proceed to the second stage only if the first-stage results meet the predefined continuation criterion. The second stage adds 15 participants, for a total of 31 participants in the decision analysis set. The maximum enrollment of 37 allows limited replacement under protocol-defined circumstances unrelated to treatment efficacy or tolerability. Participants unable to undergo surgery because of disease progression or treatment toxicity are counted as nonresponders rather than replaced.
The optional exploratory component is limited to pretreatment samples. It includes one peripheral blood collection of 20 mL for genetic analysis and the use of residual tissue from the diagnostic prostate biopsy. Tissue assessments include intraductal carcinoma of the prostate, BRCA1 and BRCA2 and other DNA repair-related gene alterations, and PTEN deletion or related abnormalities. No additional biopsy is performed for this component.
Where samples and outcome data are available, associations between baseline pathological or genetic features and pathological response, recurrence, or progression will be explored descriptively. Participation requires an affirmative choice within the study informed consent form. Declining or withdrawing from this optional component does not affect participation in the study treatment and follow-up.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Perioperative Deutenzalutamide Plus Androgen Deprivation Therapy With Neoadjuvant Docetaxel | Experimental | Drug: Deutenzalutamide, Drug: Docetaxel, Drug: ADTNeoadjuvant treatment: deutenzalutamide 80 mg orally once daily plus androgen deprivation therapy (ADT) for 24 weeks, with docetaxel 60 mg/m2 intravenously every 3 weeks for 6 cycles. Prednisone acetate 5 mg orally twice daily is given during docetaxel treatment, with subsequent tapering/discontinuation according to the protocol. When medically appropriate, participants undergo radical prostatectomy with pelvic lymph node dissection approximately 2 weeks after neoadjuvant treatment. After adequate postoperative recovery, deutenzalutamide is resumed at the last tolerated dose with ADT for 24 weeks, starting approximately 4 weeks after surgery. No postoperative docetaxel is given. ADT continues throughout for a total of at least 13 months. Dose modifications and treatment interruptions follow the protocol. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Men aged 18-80 years with histologically confirmed high-risk localized or locally advanced prostate adenocarcinoma.
- High-risk disease is defined by meeting either (1) or (2):
- No distant metastases (cM0) on baseline imaging; cN0 or pelvic cN1 below the common iliac artery bifurcation is permitted. Suitable for radical prostatectomy and pelvic lymph node dissection.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1; life expectancy >=10 years; able to receive androgen-deprivation therapy for >=13 months.
- Adequate organ function, assessed after >=14 days without blood-component transfusion or hematopoietic support: neutrophils >=1.5 x 10^9/L; platelets >=100 x 10^9/L; hemoglobin >=9 g/dL; potassium >=3.5 mmol/L; ALT and AST <=2.5 times the upper limit of normal (ULN); total bilirubin <=1.5 x ULN; creatinine <1.5 x ULN; albumin >=3.0 g/dL; international normalized ratio (INR) <1.5. Eligibility during therapeutic anticoagulation requires investigator assessment.
Key exclusion criteria (16 listed)
- Neuroendocrine/small-cell prostate carcinoma, distant metastases, or previous local or systemic treatment for prostate cancer.
- Allergy to study drugs, excipients or drugs of the same class; contraindications to docetaxel or prednisone acetate, including active infection.
- Need for chronic systemic glucocorticoids exceeding a total prednisone-equivalent dose of 10 mg/day during study treatment.
- Poorly controlled hypertension despite treatment: systolic >=160 mmHg or diastolic >=95 mmHg.
- Active or symptomatic viral hepatitis or other chronic liver disease; known HIV infection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DeutenzalutamideDeutenzalutamide 80 mg is administered orally once daily with androgen deprivation therapy (ADT) for 24 weeks before radical prostatectomy. After adequate postoperative recovery, deutenzalutamide is planned to resume approximately 4 weeks after surgery at the last tolerated dose, with ADT, for an additional 24 weeks. Dose modifications and treatment interruptions are managed according to the protocol. | Drug | Perioperative Deutenzalutamide Plus Androgen Deprivation Therapy With Neoadjuvant Docetaxel |
| DocetaxelDocetaxel 60 mg/m² is administered by intravenous infusion every 3 weeks for 6 cycles (planned at Weeks 0, 3, 6, 9, 12, and 15) during neoadjuvant treatment, in combination with deutenzalutamide and androgen deprivation therapy (ADT). Treatment interruptions and discontinuation follow protocol-defined criteria; docetaxel is not administered during postoperative adjuvant treatment. | Drug | Perioperative Deutenzalutamide Plus Androgen Deprivation Therapy With Neoadjuvant Docetaxel |
| ADTAndrogen deprivation therapy (ADT) is administered according to the prescribing information for the selected agent. Treatment begins in the neoadjuvant phase and continues through the perioperative and postoperative adjuvant phases for a total duration of at least 13 months. | Drug | Perioperative Deutenzalutamide Plus Androgen Deprivation Therapy With Neoadjuvant Docetaxel |
Primary outcome
Pathological Complete Response or Minimal Residual Disease (pCR/MRD) Rate
Time frame: At postoperative pathological assessment (surgery planned approximately 26 weeks after treatment initiation; qualifying surgery within 56 days after the actual end of neoadjuvant treatment).
Percentage of participants in the prespecified primary efficacy decision analysis set who achieve pCR or MRD on pathological examination of radical prostatectomy and pelvic lymph node dissection specimens after neoadjuvant treatment. pCR is defined as no identifiable residual cancer in the prostate (ypT0) and no regional lymph node metastasis (ypN0). MRD is defined as residual cancer confined to the prostate (ypT2 or lower), with the largest residual tumor focus measuring no more than 5 mm in greatest dimension, and ypN0. Both require no confirmed distant metastasis at assessment. Each participant is counted once. Participants unable to undergo surgery within 56 days after the actual end of neoadjuvant treatment because of disease progression, treatment toxicity or intolerance are counted as nonresponders. Other unassessable cases are handled according to the prespecified protocol rules.
20 secondary outcomes
Metastasis-Free Survival (MFS)
Time frame: From the first dose of study anticancer treatment to distant metastasis or death, whichever occurs first, with follow-up through 60 months after the end of all study treatment.
Event-Free Survival (EFS)
Time frame: From the first dose of study anticancer treatment to the first qualifying EFS event, with follow-up through 60 months after the end of all study treatment.
Time to Distant Metastasis
Time frame: From the first dose of study anticancer treatment to the first confirmed distant metastasis, with follow-up through 60 months after the end of all study treatment.
Time to First Subsequent Anticancer Therapy
Time frame: From the first dose of study anticancer treatment to initiation of the first subsequent anticancer therapy, with follow-up through 60 months after the end of all study treatment.
Biochemical Recurrence-Free Survival (bRFS)
Time frame: From radical prostatectomy to biochemical recurrence or death, whichever occurs first, with follow-up through 60 months after the end of all study treatment.
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time frame: From the first dose of protocol-specified anticancer treatment through 30 days after the end of all study treatment.
Percentage of Participants With Grade 3 or Higher Adverse Events
Time frame: From the first dose of protocol-specified anticancer treatment through 30 days after the end of all study treatment.
Percentage of Participants With Serious Adverse Events (SAEs)
Time frame: From the first dose of protocol-specified anticancer treatment through 30 days after the end of all study treatment.
Percentage of Participants With Adverse Events Leading to Study Drug Interruption, Dose Modification, or Permanent Discontinuation
Time frame: From the first dose of protocol-specified anticancer treatment through 30 days after the end of all study treatment.
Percentage of Participants With Treatment-Related Deaths
Time frame: From the first dose of protocol-specified anticancer treatment through 30 days after the end of all study treatment.
Serum Prostate-Specific Antigen (PSA) Level at the End of Neoadjuvant Treatment
Time frame: At the end of neoadjuvant treatment (planned at Week 24), before radical prostatectomy.
Serum Prostate-Specific Antigen (PSA) Levels After Radical Prostatectomy and During Adjuvant Treatment
Time frame: At adjuvant treatment baseline (approximately 4 weeks after radical prostatectomy) and at adjuvant Weeks 4, 8, 12, 16, 20, and 24/end of treatment.
Pathological Primary Tumor Stage (ypT) After Neoadjuvant Treatment
Time frame: At final postoperative pathological assessment following radical prostatectomy (surgery planned approximately 26 weeks after treatment initiation).
Pathological Regional Lymph Node Stage (ypN) After Neoadjuvant Treatment
Time frame: At final postoperative pathological assessment following radical prostatectomy (surgery planned approximately 26 weeks after treatment initiation).
Composite Pathological Downstaging Rate (T and/or N)
Time frame: From pretreatment baseline to final postoperative pathological assessment (surgery planned approximately 26 weeks after treatment initiation).
Positive Surgical Margin Rate
Time frame: At final postoperative pathological assessment following radical prostatectomy (surgery planned approximately 26 weeks after treatment initiation).
Objective Response Rate (ORR) at the End of Neoadjuvant Treatment
Time frame: At the end of neoadjuvant treatment (planned at Week 24), before radical prostatectomy.
Radical Prostatectomy Rate
Time frame: During the surgical phase following neoadjuvant treatment (radical prostatectomy planned approximately 26 weeks after treatment initiation).
Rate of Radical Prostatectomy Delay Due to Treatment-Related Adverse Events
Time frame: From initiation of neoadjuvant treatment through the surgical phase (radical prostatectomy planned approximately 26 weeks after treatment initiation).
Incidence and Severity of Postoperative Complications
Time frame: From radical prostatectomy through the adjuvant baseline visit (approximately 4 weeks postoperatively), with additional assessment at adjuvant Week 4 (approximately 8 weeks postoperatively) as clinically indicated.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Prostate Cancer (Adenocarcinoma)
RecruitingPhase 2
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Adenocarcinoma, Prostate Cancer
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingObservational study
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Prostate Cancer, Prostate Adenocarcinoma
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Deutenzalutamide, Docetaxel and ADT in people with Prostate Cancer (Adenocarcinoma), run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Wen Dong (+86 13430350469, Wendong1210@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pathological Complete Response or Minimal Residual Disease (pCR/MRD) Rate (time frame: At postoperative pathological assessment (surgery planned approximately 26 weeks after treatment initiation; qualifying surgery within 56 days after the actual end of neoadjuvant treatment).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.